Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281992009> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4281992009 abstract "Abstract Purpose: For the assessment and staging of metabolic diseases such as obesity and type 2 diabetes mellitus (T2DM), fasting plasma lactate (FPL) has been a useful marker. However, it has never been used to evaluate nonalcoholic fatty liver disease (NAFLD). Since NAFLD is one of the significant metabolic syndromes, we investigated whether FPL can be used as a biomarker for diagnosing and staging NAFLD. Methods: A total of 102 patients who were diagnosed with NAFLD and 100 healthy control between October 2018 and September 2019 were enrolled in our study. We determined the levels of FPL, total cholesterol(TC), triglycerides (TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting plasma glucose (FPG), fasting insulin(FINS), and homeostasis model assessment of insulin resistance (HOMA-IR). We performedreceiver operating characteristic (ROC) analysis to evaluate their diagnostic performance. Results: In NAFLD patients, we found FPL, ALT, AST, TG, FPG, FINS, and HOMA-IR levels to be elevated while HDL-C level was reduced (P < 0.05). FPL, FPG, FINS, and HOMA-IR levels were higher in mild NAFLD patients than moderate to severe ones (P < 0.05). For NAFLD diagnosis and staging, the areas under the ROC curve (AUC) of FPL were 0.973 and 0.999, making it clearly (P < 0.05) superior to other biomarkers.For diagnosing and staging NAFLD, the cutoff value of1.285 mmol/L and 2.370 mmol/L for FPL had the highest validity, respectively. The sensitivity, specificity, negative likelihood ratio (LR-), and positive likelihood ratio (LR+) were 87.25%, 98.00%, 0.13, and 43.63 for the diagnosis cutoff value and. 92.19%, 97.37%, 0.08, and 35.05 for staging, respectively.In addition, for NAFLD patients, FPL positively correlated with TG, FPG, FINS, and HOMA-IR (P < 0.05). Conclusion: Thus, in adult NAFLD, FPL can be used as a diagnosis and staging biomarker with superior performance." @default.
- W4281992009 created "2022-06-13" @default.
- W4281992009 creator A5004243536 @default.
- W4281992009 creator A5004653210 @default.
- W4281992009 creator A5020559342 @default.
- W4281992009 creator A5042687758 @default.
- W4281992009 creator A5046833171 @default.
- W4281992009 creator A5056559103 @default.
- W4281992009 creator A5071409252 @default.
- W4281992009 creator A5071645063 @default.
- W4281992009 creator A5086654042 @default.
- W4281992009 date "2022-05-31" @default.
- W4281992009 modified "2023-09-26" @default.
- W4281992009 title "Fasting plasma lactate: A diagnosis and staging biomarker with superior performance in adult nonalcoholic fatty liver disease" @default.
- W4281992009 doi "https://doi.org/10.21203/rs.3.rs-1663406/v1" @default.
- W4281992009 hasPublicationYear "2022" @default.
- W4281992009 type Work @default.
- W4281992009 citedByCount "0" @default.
- W4281992009 crossrefType "posted-content" @default.
- W4281992009 hasAuthorship W4281992009A5004243536 @default.
- W4281992009 hasAuthorship W4281992009A5004653210 @default.
- W4281992009 hasAuthorship W4281992009A5020559342 @default.
- W4281992009 hasAuthorship W4281992009A5042687758 @default.
- W4281992009 hasAuthorship W4281992009A5046833171 @default.
- W4281992009 hasAuthorship W4281992009A5056559103 @default.
- W4281992009 hasAuthorship W4281992009A5071409252 @default.
- W4281992009 hasAuthorship W4281992009A5071645063 @default.
- W4281992009 hasAuthorship W4281992009A5086654042 @default.
- W4281992009 hasBestOaLocation W42819920091 @default.
- W4281992009 hasConcept C126322002 @default.
- W4281992009 hasConcept C134018914 @default.
- W4281992009 hasConcept C2776954865 @default.
- W4281992009 hasConcept C2777391703 @default.
- W4281992009 hasConcept C2778772119 @default.
- W4281992009 hasConcept C2779134260 @default.
- W4281992009 hasConcept C2779306644 @default.
- W4281992009 hasConcept C2781197716 @default.
- W4281992009 hasConcept C2992872382 @default.
- W4281992009 hasConcept C55493867 @default.
- W4281992009 hasConcept C555293320 @default.
- W4281992009 hasConcept C71924100 @default.
- W4281992009 hasConcept C86803240 @default.
- W4281992009 hasConcept C90924648 @default.
- W4281992009 hasConceptScore W4281992009C126322002 @default.
- W4281992009 hasConceptScore W4281992009C134018914 @default.
- W4281992009 hasConceptScore W4281992009C2776954865 @default.
- W4281992009 hasConceptScore W4281992009C2777391703 @default.
- W4281992009 hasConceptScore W4281992009C2778772119 @default.
- W4281992009 hasConceptScore W4281992009C2779134260 @default.
- W4281992009 hasConceptScore W4281992009C2779306644 @default.
- W4281992009 hasConceptScore W4281992009C2781197716 @default.
- W4281992009 hasConceptScore W4281992009C2992872382 @default.
- W4281992009 hasConceptScore W4281992009C55493867 @default.
- W4281992009 hasConceptScore W4281992009C555293320 @default.
- W4281992009 hasConceptScore W4281992009C71924100 @default.
- W4281992009 hasConceptScore W4281992009C86803240 @default.
- W4281992009 hasConceptScore W4281992009C90924648 @default.
- W4281992009 hasLocation W42819920091 @default.
- W4281992009 hasOpenAccess W4281992009 @default.
- W4281992009 hasPrimaryLocation W42819920091 @default.
- W4281992009 hasRelatedWork W2044823377 @default.
- W4281992009 hasRelatedWork W2124038922 @default.
- W4281992009 hasRelatedWork W2169206971 @default.
- W4281992009 hasRelatedWork W2353844315 @default.
- W4281992009 hasRelatedWork W2364040497 @default.
- W4281992009 hasRelatedWork W2378305554 @default.
- W4281992009 hasRelatedWork W2608153159 @default.
- W4281992009 hasRelatedWork W3047320483 @default.
- W4281992009 hasRelatedWork W4225137284 @default.
- W4281992009 hasRelatedWork W4317861042 @default.
- W4281992009 isParatext "false" @default.
- W4281992009 isRetracted "false" @default.
- W4281992009 workType "article" @default.